⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982391 | 1.00 | — | — | |
| SCHEMBL593908 | 1.00 | — | — | |
| Methacrylic Acid SCHEMBL6671738 | 0.87 | CYP2D6 (0.52) | — | |
| SCHEMBL21359205 | 0.80 | CYP2D6 (0.70) | — | |
| SCHEMBL10777363 | 0.80 | CYP2D6 (0.42) | — | |
| SCHEMBL402167 | 0.80 | — | — | |
| SCHEMBL941571 | 0.80 | EPHX1 (0.43) | — | |
| SCHEMBL13268469 | 0.79 | CYP2D6 (0.61) | — | |
| SCHEMBL20501588 | 0.79 | CYP2D6 (0.61) | — | |
| SCHEMBL17183910 | 0.79 | CYP2D6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | claimed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | claimed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | claimed |
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | claimed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | claimed |
| JP-2007509075-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-4397665-A2 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11981657-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | EPIGENETIX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240140964-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |